NCT06954961 - A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | Biotech Hunter

Enrollment

640

Participants

Timeline

Start Date

September 15, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2028

Conditions

Breast Cancer

Interventions

DRUG

D-0502

"* Dosage form: Tablet~* Administration route: Oral, once a day"

DRUG

Fulvestrant

"* Dosage form: Injection~* Administration route: Intramuscular injection, once a month, and another dose administered two weeks after the first dose"

Trial Locations (2)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Science, Beijing

150081

RECRUITING

Harbin Medical University Cancer Hospital, Harbin